News | August 02, 2011

NIH Awards $84 Million Grant to Compare Coronary Artery Disease Management Strategies

Aug. 2, 2011 — New York University (NYU) Langone Medical Center received an $84 million grant from the National Heart, Lung and Blood Institute (NHLBI) to study the comparative effectiveness of two management strategies for patients with coronary artery disease (CAD). NHLBI is part of the National Institutes of Health (NIH).

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) is a randomized controlled trial that will study 8,000 patients with stable ischemic heart disease (SIHD) and moderate to severe ischemia. It will enlist the collaboration of more than 150 medical centers around the United States and hundreds of sites in 33 countries worldwide.

The grant is the largest ever awarded to NYU Langone Medical Center and one of the largest ever awarded by NIH for a comparative effectiveness trial.

"NYU Langone is committed to conducting leading-edge research, such as the ISCHEMIA trial, to contribute to the body of comparative effectiveness research to equip physicians with clinical evidence to inform medical decisions," said Robert I. Grossman, M.D., dean and CEO of NYU Langone Medical Center. "Leading a trial of this size and scope is an exciting opportunity to demonstrate our commitment to excellence – not only to patients, but to the medical, scientific, and health policy communities."

The study will determine the comparative effectiveness of a routine early invasive strategy (INV) with cardiac catheterization plus revascularization and optimal medical therapy (OMT) and lifestyle changes to a conservative strategy of OMT. The latter would reserve invasive procedures for failure of the first strategy in patients with moderate to severe ischemia. The Cardiovascular Clinical Research Center at NYU will handle clinical coordination.

The trial will also assess whether INV improves angina-related quality of life. The other clinical trial core functions of ISCHEMIA will take place at different U.S. sites. Duke Clinical Research Institute will be the statistical and data coordinating center, and it will also serve as the coordinating center for the cost economics and quality of life. Emory School of Medicine will be the ischemia imaging coordinating center.

"The medical community agrees further study is necessary to better determine the need for an invasive strategy and the value of revascularization when treating this patient population," said study chair Judith Hochman, M.D., MA, clinical chief of the division of cardiology, co-director of the Clinical Translational Science Institute. "With the NIH grant, we have the opportunity to collaborate with other cardiology thought leaders from around the country and world who share our urgency in learning more about what therapies offer optimal outcomes for patients in the most cost effective manner."

"This multicenter, international study provides a unique research opportunity that could yield vital information to guide clinical practice and improve quality of life and overall medical care for large, diverse populations," said Susan B. Shurin, M.D., acting director of the NHLBI.

In addition to Hochman serving as study chair, the ISCHEMIA leadership committee includes faculty from Vanderbilt University, Columbia University, The University of New York at Buffalo, East Carolina University, Duke University, Brigham and Women's Hospital, and staff from the NHLBI.

NIH funded more than seventy percent of the $259 million in research grants awarded to NYU Langone Medical Center in the fiscal year of 2010. The same year, baseline NIH funding grew from $126.4 million to $138.1 million – a 9 percent increase from the previous year and a five-fold rate increase compared to other medical schools around the country.

For more information: www.med.nyu.edu

Related Content

Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Overlay Init